The disclosure pertains to implantable medical devices for controlled delivery of therapeutic agents. Some devices according to the disclosure have a titanium reservoir, and a porous titanium oxide based membrane to control the rate of release of the therapeutic agent. The reservoir contains a formulation of the active agent, including a stabilizer for the active agent, wherein the stabilizer is provided in an extended-release configuration or a sustained release carrier.

A paranasal and/or nasal delivery system that includes a thermoresponsive gel; and a plurality of microparticles comprising a therapeutic amount of at least one paranasal and/or nasal condition-treating therapeutic agent, wherein the microparticles are included in the thermoresponsive gel.

Extended-release injectable microsphere formulations comprising ketamine are provided. Methods for making and using the microsphere formulations are also provided.

A method for formation of a vaccine comprising combining a cationic polymer adjuvant with an antigen to form first immunoparticles through charge interactions and producing a treatment formulation for the vaccine comprising the first immunoparticles.

The present invention relates to a kit for preparing a nanoparticle composition for drug delivery and, more specifically, to a kit for preparing a nanoparticle composition for drug wherein the kit is designed such that the kit does not comprise a polylactic acid salt and nanoparticles containing a drug encapsulated therein can be easily formed just by simply mixing an amphiphilic block copolymer, a cationic compound, and a drug as components of the kit.

Sustained release formulations of opioid antagonists containing both free and encapsulated opioid antagonist are described herein.

The present invention provides parenteral pharmaceutical compositions comprising therapeutically effective amounts of semaglutide or pharmaceutically acceptable salts thereof, the parenteral pharmaceutical compositions are formulated in depot form and provide low-burst release and a continued release profile. The present invention further provides methods of use of the parenteral pharmaceutical compositions for treating type-2 diabetes mellitus, obesity, and Parkinson's disease.

The invention concerns an extruded depot form for sustained active substance release, comprising at least one active substance, at least one first compound from the class of biodegradable organic polymers based on lactic acid and/or glycolic acid and at least one second compound from the class of lipids.

The present disclosure relates to dosage forms for extended release of an antibody or large protein. The extended release dosage forms comprise a biodegradable multi-block copolymer matrix and provide for extended release of antibody or large protein over a desired time period.

The present invention relates to systems and methods for the treatment of conditions of chronic inflammation, such as periodontitis, that includes the use of sustained release microparticles to locally deliver a compound or agent to reduce inflammation of tissue, such as periodontal tissue, and/or inflammatory mediators. The microparticles are loaded with a compound or agent selected from the group consisting of C-C motif chemokine ligand 2 (CCL2), interleukin 4 (IL-4), anti-interleukin 17 (IL17 antibody), and mixtures or blends thereof